Skip to content
drillr.ai
Sign up

300642.SZ

Tellgen Corp.

SZSE · Healthcare · C 制造业 · CN

CNY 13.50
−1.53%
Ask drillr

  • Sep 18, 2026, 11:23 UTC

    Shanghai Tellgen Life Science's controlling subsidiaries Jiangxi Tellgen and Maishi Biology obtained two medical device registration certificates from the Jiangxi and Shanghai drug regulators for an automated flow fluorescence immunoassay analyzer and a four-item antiepileptic drug concentration assay kit.

    Source:

  • Sep 3, 2026, 12:51 UTC

    Shanghai Rongzhen Investment Group, a specific shareholder of Tellgen Corporation, announced plans to reduce its stake by up to 0.77% of total shares via centralized bidding between September 9 and December 8, 2026.

    Source:

  • Aug 25, 2026, 12:00 UTC

    Tellgen Corporation reported its 2026 half-year results: revenue of 187.3439 million yuan, up 17.78% year-on-year; net profit attributable to shareholders of 11.4765 million yuan, up 315.92% year-on-year, partly due to the consolidation of Wuhan Kanglu Biotechnology Co., Ltd.

    Source:

  • Aug 24, 2026, 11:23 UTC

    Shanghai Tellgen Life Science announced a cash dividend of 0.50 yuan per 10 shares (tax included).

    Source:

  • Aug 12, 2026, 08:25 UTC

    Tellgen Corporation and its subsidiary Mise Bio submitted six medical device registration applications that were accepted by the Shanghai Municipal Drug Administration for review.

    Source: